UMIN000051126
Comparison of Lenvatinib with radiofrequency ablation and radiofrequency ablation alone with radiofrequency ablation planned hepatocellular carcinoma : randomized, prospective, multicenter trial
Lenvatinib - radiofrequency ablation study
SHIN-YURIGAOKA General Hospital·University Hospital Medical Information Network·drugEnrolling by invitation
Study focus
- Disease/Condition
- Hepatocellular carcinoma
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- SHIN-YURIGAOKA General Hospital
- Location
- Japan
Timeline & enrollment
- Phase
- N/A
- Start date
- May 12, 2023
- End date
- N/A
ICD-10 classifications
Malignant neoplasm: HepatoblastomaMalignant neoplasm: Liver cell carcinomaMalignant neoplasm: Other specified carcinomas of liverMalignant neoplasm: Liver, unspecifiedMalignant neoplasm: Hepatic flexure
Data source
- Registry
- University Hospital Medical Information Network
- Trial ID
- UMIN000051126
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for UMIN000051126 through Pure Global AI's free database. This phase not specified trial is sponsored by SHIN-YURIGAOKA General Hospital and is currently Enrolling by invitation. The study focuses on Hepatocellular carcinoma.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to University Hospital Medical Information Network data, helping medical device and pharmaceutical companies navigate clinical research efficiently.